TCR-engineered T cells involve genetically modifying T cells to express TCRs specific for cancer antigens. This approach, known as adoptive cell therapy, allows for the amplification of T cells that can specifically target and kill tumor cells. Engineered TCRs are designed to enhance the affinity and specificity for tumor antigens, potentially increasing the efficacy of the immune response against cancer.
